Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 665-673

  Nikiforuk, Agnieszka ^a   Popik, Piotr ^a,b   Drescher, Karla U ^c   Van Gaalen, Marcel ^c   Relo, Ana Lucia ^c   Mezler, Mario ^c   Marek, Gerard ^c   Schoemaker, Hans ^c   Gross, Gerhard ^c   Bespalov, Anton ^c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; LY 487379; METABOTROPIC RECEPTOR AGONIST; METHYLAMINE; N [4 (2 METHOXYPHENOXY)PHENYL N (2,2,2 TRIFLUOROETHYLSULFONYL)PYRID 3 YLMETHYLAMINE; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BRAIN LEVEL; COGNITION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXTRACELLULAR SPACE; IMPULSIVENESS; IN VIVO STUDY; INHIBITION (PSYCHOLOGY); MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REINFORCEMENT; SEROTONIN BRAIN LEVEL; TASK PERFORMANCE; TREATMENT RESPONSE;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOPAMINE; GLUTAMIC ACID; IMPULSIVE BEHAVIOR; MALE; MICRODIALYSIS; NOOTROPIC AGENTS; NOREPINEPHRINE; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; REINFORCEMENT (PSYCHOLOGY); SEROTONIN; SULFONAMIDES;

EID: 78649589979     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.170506     Document Type: Article

References (44)

1. Aultman JM and Moghaddam B (2001) Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology 153:353-364.
2. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, and Sanders-Bush E (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72:477-484.
3. Birrell JM and Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324.
4. Burnham KE, Baxter MG, Bainton JR, Southam E, Dawson LA, Bannerman DM, and Sharp T (2010) Activation of 5-HT(6) receptors facilitates attentional set shifting. Psychopharmacology 208:13-21.
5. Cartmell J, Monn JA, and Schoepp DD (2000) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148:423-429.
6. Clarke HF, Walker SC, Crofts HS, Dalley JW, Robbins TW, and Roberts AC (2005) Prefrontal serotonin depletion affects reversal learning but not attentional set shifting. J Neurosci 25:532-538.
7. Elliott R, McKenna PJ, Robbins TW, and Sahakian BJ (1998) Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cognit Neuropsychiatry 3:45-70.
8. Evenden JL (1999) Varieties of impulsivity. Psychopharmacology 146:348-361.
9. Galici R, Echemendia NG, Rodriguez AL, and Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181-1187.
10. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, and Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318:173-185.
11. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, and Bifone A (2008) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 33:1690-1703.
12. Harich S, Gross G, and Bespalov A (2007) Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology 192:511-519.
13. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, Woltering T, Nakanishi S, and Mutel V (2004) Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46:907-917.
14. Homayoun H, Jackson ME, and Moghaddam B (2005) Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93:1989-2001.
15. Imre G (2007) The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev 13:444-464.
16. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, and Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179:271-283.
17. Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, and Kingston AE (2004) Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem Soc Trans 32:881-887.
18. Jolly DC, Richards JB, and Seiden LS (1999) Serotonergic mediation of DRL 72s behavior: receptor subtype involvement in a behavioral screen for antidepressant drugs. Biol Psychiat 45:1151-1162.
19. Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, and Pilc A (1999) Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831-1839.
20. Lapiz MD and Morilak DA (2006) Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137:1039-1049.
21. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, and Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242.
22. Lorrain DS, Baccei CS, Correa LD, and Bristow LJ (2005) Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels. Neuropharmacology 48:927-935.
23. Marek GJ (2002) "Antidepressant-like" activity of a metabotropic glutamate2/3 (mGlu2/3) agonist: differential reinforcement of low rate 72-sec (DRL 72-s) schedule, at the 41st Annual American College of Neuropsychopharmacology Meeting; 2002 Dec. 8-12, 2002; San Juan, Puerto Rico. American College of Neuropsychopharmacology, Nashville, TN.
24. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, and Schoemaker H (2010) Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77:317-326.
25. Marek GJ, Martin-Ruiz R, Abo A, and Artigas F (2005) The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30:2205-2215.
26. Marek GJ, Wright RA, Schoepp DD, Monn JA, and Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76-87.
27. Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352.
28. Moore NA, Rees G, and Monn JA (1999) Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats. Behav Pharmacol 10:319-325.
29. Newman LA, Darling J, and McGaughy J (2008) Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology 200:39-50.
30. Nikiforuk A and Popik P (2010) Long-lasting cognitive deficit induced by stress is alleviated by acute administration of antidepressants. Psychoneuroendocrinology doi:10.1016/j.psyneuen.2010.06.001.
31. Nikiforuk A, Gołembiowska K, and Popik P (2010) Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 20:37-48.
32. O'Donnell JM and Seiden LS (1983) Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs. J Pharmacol Exp Ther 224:80-88.
33. Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Wolfarth S, and Pilc A (2000) The role of glutamate receptors in antipsychotic drug action. Amino Acids 19:87-94.
34. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107.
35. Paxinos G and Watson C (1982) The Rat Brain in Stereotaxic Coordinates. Academic, New York.
36. Richards JB, Sabol KE, and Seiden LS (1993) DRL interresponse-time distributions: quantification by peak deviation analysis. J Exp Anal Behav 60:361-385.
37. Roberts AC, Robbins TW, and Everitt BJ (1988) The effects of intradimensional and extradimensional shifts on visual discrimination learning in humans and non-human primates. Q J Exp Psychol B 40:321-341.
38. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, et al. (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193:121-136.
39. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810.
40. Sokolowski JD and Salamone JD (1994) Effects of dopamine depletions in the medial prefrontal cortex on DRL performance and motor activity in the rat. Brain Res 642:20-28.
41. Sokolowski JD and Seiden LS (1999) The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology 147:153-161.
42. Stephens DN and Cole BJ (1996) AMPA antagonists differ from NMDA antagonists in their effects on operant DRL and delayed matching to position tasks. Psychopharmacology 126:249-259.
43. Witkin JM and Eiler WJ (2006) Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders. Drug Dev Res 67:757-769.
44. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, et al. (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiat 47:818-829.